The Cooper Companies, Inc. (Cooper) is a global medical device company, listed on the New York Stock Exchange. Cooper is headquartered in Pleasanton, California USA, with over 11,000 employees worldwide and products sold in over 100 countries. Cooper subsidiaries include CooperVision (CVI) and CooperSurgical (CSI). CVI manufactures and distributes contact lenses and contact lens products and CSI provides medical devices and procedure-based solutions to the women’s healthcare segment.

The California Transparency in Supply Chains Act of 2010 (SB 657) went into effect on January 1, 2012. The Act requires retailers and manufacturers above a certain size to disclose efforts undertaken to prevent possible slavery and human trafficking in their supply chains. The disclosure is intended to provide information to consumers, allowing them to make informed choices about the products they buy and the companies they support.

The UK Modern Slavery Act 2015 creates offences and imposes a duty on businesses supplying goods and services in the UK to report each year on the steps they have undertaken to ensure their operation and supply chains are free of human trafficking and slavery. Other countries have similar laws and requirements.

The Cooper Companies, Inc., together with its subsidiaries is committed to supporting human rights globally within our own organization and within its external supply base. Cooper expects its suppliers to comply with all applicable regulations and laws. Cooper fully supports the intent of California’s and the UK’s laws and opposes human trafficking and slavery in all forms.

Supplier Evaluation, Qualification and Verification

Cooper uses a risk-based assessment process for evaluating, verifying and selecting direct suppliers. Cooper expects all of its suppliers to abide by all applicable laws and regulations and maintain the highest ethical standards.

Supplier Agreements and Code of Conduct

In its supply agreements, contracts, purchase orders and other arrangements with its direct suppliers, Cooper includes provisions requiring such direct suppliers to comply with applicable laws and regulations, including as relates to the products or materials being supplied. Furthermore, Cooper’s Supplier Code of Conduct mandates that Suppliers shall not participate in human trafficking; use any indentured or forced labor, slavery or servitude or purchase materials or services from companies using forced, involuntary or slave labor.

Cooper is currently reviewing its Supplier Code of Conduct to ensure that our requirements are clear and that there is a system in place to record a formal declaration from each supplier. Cooper is aiming to finalise these, and roll out, in Financial Year 2018.

---

1 This statement sets out the steps taken by The Cooper Companies and its subsidiaries, including CooperVision Manufacturing Limited, CooperVision Limited, CooperVision (UK) Holdings Limited, CooperVision Lens Care Limited, CooperSurgical Holdings Limited and Research Instruments Limited.
Training and Accountability

Cooper has adopted and implemented its Ethics and Business Conduct Policy (this “Policy”), which applies to the Company and all of its worldwide divisions, subsidiaries and affiliated companies and is to be followed by all employees. Employees who commit a material violation of this Policy may face disciplinary action, up to and including termination of employment. Materiality of a violation shall be determined on a case by case basis by the Governance Committee and shall be based on the Committee’s business judgment in its sole discretion. All employees certify on an annual basis that they have received, read, and been trained on the Ethics and Business Conduct Policy.

Cooper continues to assess and evaluate its supply chain’s responsible sourcing practices. We strive to enforce best practices in our supply chain and within the entirety of our organization.

This statement is made pursuant to section 54(1) of the Modern Slavery Act 2015 and constitutes our Group’s slavery and human trafficking statement for the financial year ending 2017. It has been approved by the Boards of CooperVision Manufacturing Limited, CooperVision Limited, CooperVision (UK) Holdings Limited, CooperVision Lens Care Limited, CooperSurgical Holdings Limited and Research Instruments Limited.

Signature
Director

Date: 23 April 2018